AstraZeneca To Reclaim Full Rights To Several Drugs From Merck For $647M

By exercising its option, AstraZeneca also positions itself to regain full rights to Nexium and Prilosec as early as 2012.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet